Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Macquarie Group Limited, along with its controlled entities, has ceased to be a substantial holder in Australian Clinical Labs Limited. This change in substantial holding may impact the company’s shareholder structure and influence its market dynamics, although specific implications for stakeholders are not detailed in the release.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Average Trading Volume: 826,101
Technical Sentiment Signal: Sell
Current Market Cap: A$549.9M
Learn more about ACL stock on TipRanks’ Stock Analysis page.